Sun Pharma Corporate Overview

Financials Market Capitalisation Rs. 1,600 billion / US$ 22 billion (as of 16th July 2021) SUN PHARMA FY17 YOY FY18 YoY FY19** YoY FY20 YoY (All Figures in Rs. Mn) FY21 YOY P&L Summary Sales 302,642 9% 260,659 -14% 286,863 10% 323,252 13% 331,392 3% Gross Profit 221,335 3% 186,413 -16% 208,173 12% 230,947 11% 244,491 6% EBITDA 87,751 16% 51,846 -41% 59,280 14% 64,774 9% 81,324 26% Net Profit 69,644 53% 20,957 -70% 26,654 27% 37,649 41% 29,038 -23% # Net Profit (Adjusted) 69,644 33% 33,006" -53% 38,798 18% 40,256 4% 59,317* 47% R&D Spend 23,138 0% 22,489 -3% 19,847 -12% 19,736 -1% 21,499 9% BS Summary Mar'17 YOY Mar'18 YOY Mar'19 YoY Mar'20 YOY Mar'21 YOY Shareholders Funds 366,397 11% 383,141 5% 414,091 8% 452,645 9% 464,628 3% Loan Funds 80,910 -3% 97,518 21% 98,934 1% 75,783 -23% 33,430 -56% Net Fixed Assets 149,404 20% 157,110 5% 172,919 10% 175,858 2% 168,322 -4% Investments 11,919 -35% 71,430 Cash and Bank Balances 151,408 15% 99,294 Inventory 68,328 6% 68,810 Sundry Debtors 72,026 6% 78,150 499% 79,025 -34% 72,756 1% 78,860 9% 11% 101,431 -27% 64,876 28% 96,125 -5% -11% 64,455 -1% 15% 78,750 0% 89,970 14% 88,840 14% 94,212 6% 90,614 -4% Sundry Creditors 43,954 23% 47,662 8% 41,479 -13% 35,836 -14% 39,737 11% # FY18 - Adjusted for Rs. 12.1 bn provision related to Modafinil settlement & deferred tax adjustment # FY19 - Adjusted for Rs. 12 bn provision related to Modafinil settlement **FY19 - Includes a one-time sales reduction of Rs. 10,850mn related to change in distribution for India business # FY20 - Adjusted for Rs. 2.6 bn provision (related to Dusa US DoJ settlement of Rs. 1.6 bn and Indirect Tax provision of Rs. 1.0 bn in India) #FY21 - Adjusted for Rs. 30.3 bn provision (related to Taro US - DOJ & MDL settlement Rs. 42.2, Rs. 0.9 bn provision related to UK Citalopram case, Rs. 4.1 bn related to deferred tax gain. Taro provisions are adjusted for minority interest) © Sun Pharmaceutical Industries Limited. All Rights Reserved. 43

View entire presentation